Inactive Instrument

Highlights TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Adaptimmune Therapeutics plc completed the acquisition of TCR2 Therapeutics Inc. from a group of shareholders.	23-05-31	CI
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-23	AQ
Wedbush Lowers TCR2 Therapeutics' Price Target to $2.18 From $4 on Heels of Adaptimmune Merger Announcement, Keeps Neutral Rating	23-03-07	MT
Adaptimmune Therapeutics, TCR2 Therapeutics to Merge in All-Stock Transaction	23-03-06	MT
Adaptimmune and TCR2 Therapeutics Inc. Announce Strategic Combination to Create Preeminent Cell Therapy Company for Solid Tumors	23-03-06	CI
Adaptimmune Therapeutics plc entered into a definitive agreement to acquire TCR2 Therapeutics Inc. from a group of shareholders for approximately $110 million.	23-03-05	CI
TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Tcr2 Therapeutics Inc. Announces Positive Topline Results from the Phase 1 Portion of the Gavo-Cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors	22-09-28	CI
TCR2 Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	22-03-22	AQ
TCR2 Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-03-22	CI
TCR2 Agrees Strategic Collaboration With Arbor Biotechnologies to Develop TRuC-T Cell Therapies	22-01-04	MT
TCR2 Therapeutics Inc. and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies	22-01-04	CI
TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Tcr2 Therapeutics Inc. Announces Expansion of U.S. Manufacturing Capacity	21-11-01	CI
TCR2 Therapeutics : Initiates Clinical Trial Partnership With Bristol Myers Squibb to Evaluate Gavo-cel in Combination With Other Drugs as Solid Tumor Treatment	21-10-25	MT
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors	21-10-25	CI
TCR2 Therapeutics Inc. Reviews Pipeline and Strategy At R&D Day	21-10-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

Highlights

Filters